STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)
Jordi Bruix(Hospital Clínic de Barcelona), Kwan Sik Lee(Gangnam Severance Hospital), Masatoshi Makuuchi(Nagano Children's Hospital), Han Chu Lee(Asan Medical Center), Masatoshi Kudo(Kindai University), Kwang‐Hyub Han(Yonsei University), Tianqiang Song(Tianjin Medical University Cancer Institute and Hospital), Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Marie‐Aude Le Berre(Bayer (France)), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Gar‐Yang Chau(Taipei Veterans General Hospital), Jiamei Yang(Jilin University), Tadatoshi Takayama(Nihon University), Gerold Meinhardt(Daiichi Sankyo (United States)), Fabrício Henrique Pereira De Souza, Ronnie Tung‐Ping Poon(Queen Mary Hospital), Luigi Bolondi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Jianqiang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College), Won Young Tak(Kyungpook National University Hospital), Sasan Roayaie(White Plains Hospital)
Cited by 60
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k